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Abstract
Background: To evaluate the type and frequency of antiretroviral drug stock-outs, and their impact on death and
interruption in care among HIV-infected patients in Abidjan, Co ˆte d’Ivoire.
Methods and Findings: We conducted a cohort study of patients who initiated combination antiretroviral therapy (cART) in
three adult HIV clinics between February 1, 2006 and June 1, 2007. Follow-up ended on February 1, 2008. The primary
outcome was cART regimen modification, defined as at least one drug substitution, or discontinuation for at least one
month due to drug stock-outs at the clinic pharmacy. The secondary outcome for patients who were on cART for at least six
months was interruption in care, or death. A Cox regression model with time-dependent variables was used to assess the
impact of antiretroviral drug stock-outs on interruption in care or death. Overall, 1,554 adults initiated cART and were
followed for a mean of 13.2 months. During this time, 72 patients discontinued treatment and 98 modified their regimen
because of drug stock-outs. Stock-outs involved nevirapine and fixed-dose combination zidovudine/lamivudine in 27% and
51% of cases. Of 1,554 patients, 839 (54%) initiated cART with fixed-dose stavudine/lamivudine/nevirapine and did not face
stock-outs during the study period. Among the 975 patients who were on cART for at least six months, stock-out-related
cART discontinuations increased the risk of interruption in care or death (adjusted hazard ratio [HR], 2.83; 95%CI, 1.25–6.44)
but cART modifications did not (adjusted HR, 1.21; 95%CI, 0.46–3.16).
Conclusions: cART stock-outs affected at least 11% of population on treatment. Treatment discontinuations due to stock-
outs were frequent and doubled the risk of interruption in care or death. These stock-outs did not involve the most
common first-line regimen. As access to cART continues to increase in sub-Saharan Africa, first-line regimens should be
standardized to decrease the probability of drug stock-outs.
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Introduction
The World Health Organization (WHO) and the Joint United
Nations Program on HIV/AIDS (UNAIDS) estimate that in late
2007, 30–36 million people were living with HIV, including 22 million
in sub-Saharan Africa and 480,000 in Co ˆte d’Ivoire [1]. The dramatic
rise in global funding for HIV/AIDS, as well as reduced drug costs,
have increased the availability of combination antiretroviral therapy
(cART) in sub-Saharan Africa [2,3]. The number of HIV-infected
patients on cART in this region has increased sharply from 100,000 in
2002 to 3 million in 2007, of whom 50,000 are in Co ˆ t ed ’ I v o i r e[ 4 ] .
With increased access to cART, drug stock-outs related to
insufficient human resources and poor infrastructure have been
reported, leading to treatment modifications or discontinuations
[5,6,7]. In an analysis of the determinants of adherence to cART
among HIV-infected patients in Co ˆte d’Ivoire, Diabate ´ et al.
reported that 10% of interruptions were related to drug stock-outs
[7]. The efficacy of cART relies on excellent adherence [8], since
cART interruptions are associated with higher rates of drug
resistance [9], opportunistic infections, and death [10].
Studies on the frequency and impact of cART stock-outs in sub-
Saharan Africa are scarce. The objectives of this study are to assess
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13414the frequency of cART stock-outs in three major HIV care centers
in Abidjan, Co ˆte d’Ivoire; to determine whether stock-outs led to
cART modifications or discontinuations; and to study the impact
of stock-out-related modifications or discontinuations on retention
in care and mortality.
Methods
Population
In 2004, Aconda, an Abidjan-based non-governmental organi-
zation, initiated a program of access to care and treatment aimed
at HIV-infected patients [11,12]. We conducted a prospective
cohort study at three Aconda HIV care centers in Abidjan, Co ˆte
d’Ivoire: the Yopougon-Attie ´ clinic, the CePReF clinic [12] and
the HIV clinic affiliated with the National Center for Blood
Transfusion (CNTS) [13]. Yopougon-Attie ´ is a general medicine
outpatient clinic, while CePReF and CNTS are outpatient clinics
entirely devoted to HIV care. Study subjects were HIV-1 or HIV-
1+2-infected adults aged $21 years (i.e; legal age in Co ˆte d’Ivoire)
who initiated cART between February 1, 2006 and June 1, 2007
in any of the three study centers and who provided written
informed consent (Figure 1). We assessed the incidence and
determinants of virologic resistance to cART in these patients.
Follow-up began at cART initiation and ended when the database
closed, on February 1, 2008.
Ethics statement
The Aconda computerized data management system has been
previously described [11,12], and has been approved by the
National Ethics Committee of Co ˆte d’Ivoire. This study was
conducted according to the principles expressed in the Declaration
of Helsinki. All patients provided written informed consent for the
collection of samples and subsequent analysis.
Definitions
Drug stock-out. Patients were retrospectively considered to
be affected by a drug stock-out if: (i) it led to a cART regimen
modification, defined as at least one drug substitution, or an
discontinuation of at least one month (i.e=prolonged discon-
tinuation); (ii) the medical record stated that the cART
modification or discontinuation had occurred due to a drug
stock-out; and (iii) the cART modification or prolonged
discontinuation occurred when there was a shortage of one of
Figure 1. HIV-infected patients on cART in three Abidjan’ HIV care centers, February 2006–February 2008. * The descriptive analysis
evaluates the frequency of treatment modifications and discontinuation that are related to drug stock-outs. { The etiologic analysis evaluates the
association between stock-out-related regimen modification or discontinuation and interruption in care or death. cART: combination antiretroviral
therapy.
doi:10.1371/journal.pone.0013414.g001
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identified drug shortage periods by analyzing pharmacy data
sheets.
Interruption in care. Patients were considered to have an
interruption in care if they: (i) did not attend scheduled clinic visits
for $3 months; (ii) did not return to care before the study ended
on February 1, 2008; (iii) were not known to be in care at any
other hospital or clinic during the study period; and (iv) were not
known to have died [12,14]. When patients did not show up for a
scheduled visit, social workers and organizations of persons living
with HIV/AIDS (PLWHA) tried to locate them by telephone or
home visits [15].
Data collection
We used a standardized monitoring system to collect detailed
demographic, clinical, laboratory and therapeutic information on
subjects in each study center. Data collected at enrollment
included age, sex, marital status, education level, phone number
and address, WHO clinical stage, CD4 count, and first-line cART
regimen. Physicians and trained technicians collected follow-up
data at each monthly visit. These data included AIDS-defining
events, cART modification or discontinuation, and cause of
modification or discontinuation. HIV RNA tests and CD4 counts
were performed every six months and data were monitored with a
standardized system.
Statistical analyses
First, we described the baseline characteristics of patients
enrolled in the study. We described quantitative variables using
medians and interquartile ranges (IQR), and compared results
from each study center using a nonparametric Wilcoxon rank-sum
test. We summarized qualitative variables using percentages and
compared results from each center using a Chi square test.
Second, we analyzed the association between stock-out-related
treatment modification or prolonged discontinuation and inter-
ruption in care or death in the 975 patients who were on cART for
at least six months during the study period (Figure 1). We
restricted the analysis to this period for two reasons. First, most
stock-outs in Aconda centers occurred between April 1, 2007 and
October 15, 2007, when most patients had been on cART for at
least six months. Second, mortality among patients on cART in
sub-Saharan Africa is consistently higher during the first six
months of treatment, when it is more likely to be related to other
factors, including treatment initiation at low CD4 counts
[12,14,15,16,17,18,19,20]. The factors associated with treatment
outcomes are thus different in the first six months and the last six
months of treatment, and our database was more appropriate for
analyzing the later period.
We did not separate retention in care and death into separate
outcomes for two reasons. First, a large proportion of patients who
were lost to follow-up likely represent unrecorded deaths as has
been reported elsewhere[15,18]. Second, we evaluated the impact
of drug stock-outs on retention in care and death in a subset of
patients who were on cART for at least six months. If we
considered these two outcomes separately, the power of the
analysis would be greatly reduced.
The interruption in care rate was defined as the number of
patients who interrupted care, divided by the total number of
person-years at risk of interruption in care. Patients were
considered to be at risk of interruption in care from six months
after cART initiation to the date of their last visit, transfer to a
different HIV care center, interruption in care, or death. Patients
who died were censored on the date of death, patients who
transferred to a different HIV care center were censored on the
date of their last visit at the study center, and patients who were
alive and in care were censored on February 1, 2008. We
estimated 95% confidence intervals using Poisson’s exact distri-
bution [21].
We stratified time to interruption in care or death according to
patient characteristics. We used the Kaplan-Meier method to
perform a time-to-event analysis, and a log-rank test to compare
survival distributions.
We used a multivariate Cox proportional hazard regression
model to examine the association between interruption in care or
death and stock-out-related cART modification or discontinua-
tion. We accounted for variations in exposure over time by making
the ‘‘modification or discontinuation’’ variable time-dependent in
the multivariate model [22]. The variable could have one of five
values: (i) no cART discontinuation or modification (reference
group); (ii) cART regimen modification due to stock-out; (iii)
cART regimen modification not due to stock-out; (iv) cART
discontinuation due to stock-out; and (v) cART discontinuation
not due to stock-out. Patients who discontinued and modified their
cART regimens were classified as having discontinued cART,
even if the modification occurred before the discontinuation.
We also examined the association between interruption in care
or death and sociodemographic variables at enrolment, as well as
clinical/biological variables six months after cART initiation,
using a multivariate Cox proportional hazard regression model.
Quantitative variables were added to the model by category, to
reduce the impact of the assumptions involved in log-linear
modelling. The categories included in the multivariate model
included age (above or below the median), body mass index (in
quartiles) and CD4 count (in clinical relevant strata). A missing
values category was created for the following variables: marital
status, distance from study center, education level, and WHO
clinical stage.
We added variables that were found to be associated with
interruption in care or death in univariate analysis (p-value
,0.25), to the multivariate model, in order to evaluate multiple
factors simultaneously. We developed the multivariate model using
a backward stepwise regression analysis [23]. In a multivariate
analysis that used Wald’s test model, results were considered to be
significant when p-values were ,0.05. In this analysis, to assess
proportionality we first generate time dependant covariates by
creating interactions of the predictors and a function of survival.
We included the resulting time dependent covariates into the Cox
model. Analyses were conducted with SASH software, version 9.1
(SAS institute Inc. Cary, North Carolina, USA
Sensitivity analyses
We conducted a sensitivity analysis on the definition of drug
stock-out, because the reason for cART modification or
discontinuation was not always noted in the medical record. In
this sensitivity analysis, drug stock-out was defined as any
treatment prolonged discontinuation (more than one month),
was not accompanied by a specific explanation in the medical
record, and occurred during a period of shortages in one of the
patient’s antiretroviral drugs, as reported by the study center
pharmacy. In a second sensitivity analysis, we only included
patients on cART regimens that included drugs affected by drug
stock-outs, because drug stock-outs did not occur for all cART
combinations.
Results
Overall, 1,554 patients initiated cART between February 1,
2006 and June 1, 2007. Baseline characteristics are shown in
Impact of ART Drug Stock-Outs
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were female, and 92% of patients lived in Abidjan. At treatment
initiation, 210 patients (15%) were at WHO clinical stage 4 and
median CD4 count was 136/ml (IQR, 57–220). Fifty four percent
of patients initiated cART with generic fixed-dose combination
stavudine/lamivudine/nevirapine. Patient characteristics differed
by study center. For example, patients at Yopougon-Attie ´ started
cART with more advanced disease than in other centers (WHO
clinical stage 4: Yopougon-Attie ´, 29% compared to CePReF, 9%
and CNTS, 9%; p,0.01). Patients at Yopougon-Attie ´ also
received stavudine/lamivudine/nevirapine less often than patients
in the other centers (Yopougon-Attie ´, 20% compared to CePReF,
67% and CNTS, 83%; p,0.01). Patients were followed for a
median of 13 months after starting cART (IQR, 7–18). Among
these 1,554 patients, during the study period, 184 patients died
(12%) and 362 had interrupted care (23%).
Of the 1,554 study subjects, 830 (53%) discontinued cART for
more than one month and 280 (18%) modified their cART
regimens at least once. Drug stock-outs led to 72 prolonged
treatment discontinuations and 98 regimen modifications, repre-
senting 11% of the 1,554 patients who started cART between
February 1, 2006 and February 1, 2007. These stock-outs were
responsible for 9% of all cART discontinuations and 30% of all
cART regimen modifications. Median time from cART initiation
to first prolonged stock-out-related discontinuation or modification
was 9 months (IQR, 5–13). Twelve percent of prolonged
discontinuations were not related to drug stock-outs, but rather
to travel, funerals, adverse events, treatment with traditional
remedies, or inability to pay for drugs. The reason for treatment
discontinuation was not noted in the medical records of 657
patients (79%). For 53 of these patients, cART discontinuations
occurred when at least one of the drugs in their regimen was not in
stock at the study center pharmacy (Table 2). When we assumed
that these patients interrupted cART because of drug stock-outs,
an estimated 16% of cART discontinuations were due to drug
stock-outs. Most cART regimen modifications at CePReF and
Table 1. Baseline characteristics of 1,554 HIV-infected adults who started cART in HIV care centers of the Aconda program in
Abidjan, Co ˆte d’Ivoire.
CePReF Yopougon-Attie CNTS Total
{ p
Mean, years/mean (IQR)/N=1553
{ 36.1 (30.2–42.9) 35.3 (29.5–42.3) 35.2 (30,3–42,6) 35(25.9–42.7) 0.57
{
Gender, n (%) 904 485 162 1551 ,0.01*
Female 651(72.0) 379 (78.1) 109 (67.3) 1139 (73.4)
Marital status, n (%) 899 362 160 1421 ,0.01
Single 356 (39.6) 224 (61.9) 84 (52.5) 664 (46.7)
Married 501 (55.7) 76 (21.0) 57 (35.6) 634 (44.6)
Divorced or widower 42 (4.7) 62 (17.1) 19 (11.9) 123 (8.7)
Educational level, n (%) 631 303 116 1050 0.17
Illiterate or primary school 238 (37.7) 133 (43.9) 35 (30.2) 406 (38.7)
Secondary school or higher 393 (62.3) 170 (56.1) 81 (69.8) 644 (61.3)
Distance to care center, n (%) 860 467 155 1482 ,0.01
,50 km, from Abidjan 777 (90.3) 451 (96.6) 140 (90.3) 1368 (92.3)
50–250 km 41 (4.8) 9 (1.9) 10 (6.5) 60 (4.0)
.250 km 42 (4.9) 7 (1.5) 5 (3.2) 54 (3.7)
WHO clinical stage, n (%) 870 432 90 1392 ,0.01
1 29 (3.3) 2 (0.5) 31 (34.4) 62 (4.4)
2 132 (15.2) 53 (12.3) 33 (36.7) 218 (15.7)
3 632 (72.6) 252 (58.3) 18 (20.0) 902 (64.8)
4 77 (8.9) 125 (28.9) 8 (8.9) 210 (15.1)
BMI/ mean (IQR)/ N=1064
{ 19.8 (17.8–22.2) 19.9 (17.6–22.4) 21.0 (18.4–23.1) 19.9 (17.8–22.4) 0.04
CD4 cells/ml/mean (IQR)/N=1520
{ 139 (54–222) 135 (59–233) 132 (60–184) 136 (57–220) 0.14
First-line ART regimen, n (%) 903 487 162 1552 ,0.01
ZDV/3TC/EFV 176 (19.4) 233 (47.9) 9 (5.6) 418 (26.9)
d4T/3TC/EFV 74 (8.2) 78 (16.0) 11 (6.8) 163 (10.5)
d4T/3TC/NVP 605 (67.0) 100 (20.5) 134 (82.7) 839 (54.1)
ZDV/3TC/NVP 5 (0.6) 33 (6.8) 0 38 (2.4)
Other 43 (4.8) 43 (8.8) 8 (4.9) 94 (6.1)
*x
2 test; { Wilcoxon rank-sum test.
{Numbers do not add up to 1,554 because of missing values.
CNTS: HIV clinic affiliated with the National Center for Blood Transfusion;
ZDV: zidovudine; 3TC: lamivudine; d4T: stavudine; EFV: efavirenz; NVP: nevirapine.
Other cART regimens: zidovudine-lamivudine-indinavir/ritonavir, lamivudine-stavudine-indinavir/ritonavir, or stavudine-abacavir-efavirenz.
BMI: Body Mass Index; virological failure: plasma HIV RNA.300 copies/ml.
IQR: Inter quartile range.
doi:10.1371/journal.pone.0013414.t001
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At Yopougon-Attie ´, the majority of modifications occurred
because of drug stock-outs (54% compared to 26% at CePReF
and 19% at CNTS; p,0.01).
The first major drug stock-out was a shortage of fixed-dose
zidovudine/lamivudine from April 1 to May 15, 2007 at CePReF
and from May 1 to May 31, 2007 at Yopougon-Attie ´( Figure 2).
There was also a shortage of nevirapine from July 1 to September
15, 2007 at CePReF and from August 27 to October 10, 2007 at
CNTS. Patients taking nevirapine and fixed-dose zidovudine/
lamivudine were affected by stock-outs most frequently, in 27%
and 51% of cases, respectively. Stavudine/lamivudine/nevirapine,
the most frequently prescribed regimen was not associated with
any stock-outs and was always available. The proportion of stock-
out-related cART discontinuations decreased over time (Figure 2;
Cochran-Armitage test for trend p,0.01).
Table 2. Reasons for treatment modifications and discontinuations, by period, in 1,554 HIV-infected adults who started cART in
HIV care centers of the Aconda program in Abidjan, Co ˆte d’Ivoire.
Before 6 months n (%) After 6 months n (%) Total n (%)
Reasons for cART modification N=52 N=277 N=329*
Adverse event 24 (46.1) 133 (48.0) 157 (47.4)
Drug stock-out 10 (19.2) 88 (31.8) 98 (30.0)
Tuberculosis 14 (26.9) 22 (7.9) 36 (11.0)
Pregnancy 0 (0) 13 (4.7) 13 (4.0)
Treatment failure 0 (0) 6 (2.2) 6 (1.8)
Unknown 4 (7.7) 15 (5.4) 19 (5.8)
Reasons for prolonged cART discontinuations N=295 N=535 N=830
Drug stock-out 8 (2.7) 65 (12.2) 73 (8.8)
Other
{ 42 (14.2) 58 (10.8) 100 (12.1)
Unknown 245 (83.1) 412 (77.0) 657 (79.1)
Not during antiretroviral drug stock-out period 229 (77.6) 375 (70.1) 604 (72.8)
During antiretroviral drug stock-out period 16 (5.4) 37 (6.9) 53 (6.3)
*: The total number of patients who modified their treatment is 280. Total of cART modifications, different from 280 because patients can undergo several modifications.
{: Travel, adverse events occurrence, funeral, treatment with traditional remedies, inability to pay for drugs.
doi:10.1371/journal.pone.0013414.t002
Figure 2. Diagram of main drugs affected by stock-outs in the Aconda program, February 2006–February 2008. CNTS: HIV care center
affiliated with the National Center for Blood Transfusion. NVP: Nevirapine. ZDV-3TC: Zidovudine/lamivudine. * Proportion of patients who interrupt
antiretroviral therapy=number of patients who interrupt therapy due to drug stock-outs/number on that therapy during this period. ¥ Month/day/
year.
doi:10.1371/journal.pone.0013414.g002
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Overall, 975 patients were followed for at least six months
(Figure 1). Median CD4 count six months after cART initiation
was 295/ml (IQR, 196–432) and 20% of patients had plasma HIV
RNA.300 copies/ml. Compared to patients who died, had
interrupted care, or transferred to a different HIV care center
within the first six months of cART initiation , patients who
remained on cART were older at cART initiation (37 versus 35
years; p=0.03), had less advanced HIV disease (WHO Stage 4,
12% vs. 22%; p,0.01), and were more likely to have initiated
cART with fixed-dose stavudine/lamivudine/nevirapine (58% vs.
46%; p,0.01).
Patients were followed for a mean additional time of 10 months
(IQR: 6–13 months) after being followed on cART for six months.
During this time, 26 patients died and 94 had interruption in care
(Figure 1). The incidence of interruption in care was estimated at
14.5 per 100 person-years (PY; 95% CI, 14.2–14.7) and the
mortality rate was 3.5/100PY (95% CI, 2.8–4.2). In patients who
were still on cART six months after initiation, the probability of
being alive and in care 18 months after cART initiation was 0.85
(95% CI, 0.82–0.87).
Of the 975 patients who were on cART for at least six months,
148 (15%) discontinued or modified their regimen because of drug
stock-outs. As shown in Table 3, stock-out-related discontinuations
were independently associated with a higher risk of interruption in
care or death compared to no discontinuations or modifications
(adjusted hazard ratio [HR], 2.83; 95% CI, 1.25–6.44). In contrast,
stock-out-related regimen modifications did not have a significant
impact on the outcome (adjusted HR, 1.21; 95% CI, 0.46–3.16).
Other factors associated with an increased risk of interruption in
care or death were plasma HIV RNA.300 copies/ml at month 6
(adjusted HR, 2.24; 95% CI, 1.50–3.33), cART regimens that did
not contain any non-nucleoside reverse transcriptase inhibitors
(NNRTI; adjusted HR, 2.49; 95% CI, 1.31–4.71), cART regimen
modifications not related to drug stock-outs (adjusted HR, 3.38;
95% CI, 1.47–7.44) and cART discontinuations not related to drug
stock-outs (adjusted HR, 2.78; 95% CI, 1.77–4.37). Interruption of
care and death were not significantly associated with study center,
age, gender, distance from HIV care center, WHO clinical stage or
baseline CD4 counts.
Results remained robust in the sensitivity analysis on the
definition of drug stock-out. Stock-out-related discontinuations
Table 3. Factors independently associated with interruption in care or death among 975 HIV-infected patients in care 6 months
after cART initiation, Abidjan, Co ˆte d’Ivoire; basecase and sensitivity analysis on drug stock-out definition.
Basecase Analysis Sensitivity analysis**
Interruption in care/death, n (%) HR 95% CI p HR 95% CI p
Yes No
cART discontinuation or modification
None 30 (8.82) 310 (91.18) 1.00 ,0.01
* 1.00 ,0.01
*
Modification/stock-out 5 (5.95) 79 (94.05) 1.21 0.46–3.16 0.70 1.22 0.46–3.02 0.68
Modification/other reasons 7 (11.29) 55 (88.71) 3.38 1.47–7.74 ,0.01 3.40 1.49–7.80 0.01
Discontinuation/stock-out 8 (12.50) 56 (87.50) 2.83 1.25–6.44 0.01 3.09 1.36–7.05 0.01
Discontinuation/other reasons 69 (16.39) 352 (83.61) 2.78 1.77–4.37 ,0.01 2.80 1.78–4.40 ,0.01
Study center
CePReF 56 (8.90) 573 (91.10) 1.00 0.13
* 1.00 0.13
*
CNTS 17 (17.17) 82 (82.83) 1.52 0.86–2.69 0.15 1.52 0.86–2.69 0.15
Yopougon-Attie 46 (18.93) 197 (81.07) 1.53 0.95–2.45 0.08 1.54 0.96–2.47 0.07
First-line cART regimen
d4T/3TC/NVP 59 (10.39) 509 (89.61) 1.00 0.02
* 1.00 0.02
*
ZDV/3TC/EFV 29 (11.65) 220 (88.35) 0.93 0.56–1.56 0.78 0.91 0.55–1.53 0.73
d4T/3TC/EFV 14 (15.05) 79 (84.95) 1.71 0.92–3.17 0.09 1.71 0.92–3.17 0.09
ZDV/3TC/NVP 4 (23.53) 13 (76.47) 1.44 0.49–4.25 0.51 1.41 0.48–4.18 0.53
Other 13 (29.55) 31 (70.45) 2.49 1.31–4.71 ,0.01 2.46 1.30–4.67 0.01
Virological failure (6 months)
No 78 (9.87) 712 (90.13) 1.00 ,0.01 1.00 ,0.01
Yes 41 (22.65) 140 (77.35) 2.24 1.50–3.33 2.24 1.50–3.33
HR: hazard ratio, adjusted for all variables in the table;
CNTS: HIV clinic affiliated with the National Center for Blood Transfusion;
ZDV: zidovudine; 3TC: lamivudine; d4T: stavudine; EFV: efavirenz; NVP: nevirapine.
Other cART regimens: zidovudine-lamivudine-indinavir/ritonavir, lamivudine-stavudine-indinavir/ritonavir, or stavudine-abacavir-efavirenz.
Other reasons for modifications are: adverse events, tuberculosis, pregnancy and treatment failure. The reason for modification was unknown for 18 patients (6%).
Other reasons for discontinuations are: travel, adverse events, funeral, treatment with traditional remedies, or inability to pay for drugs. The reason for discontinuation
was unknown for 657patients (79%).
Virologic failure: plasma HIV RNA.300 copies/ml.
*Overall p value.
**The sensitivity analysis uses an expanded definition of drug stock-out, which includes any treatment discontinuation that lasted more than one month, was not
accompanied by an explanation in the medical record, occurred when the pharmacy reported a shortage of at least one of the drugs in the patient’s cART regimen.
doi:10.1371/journal.pone.0013414.t003
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or death (adjusted HR, 3.09; 95% CI, 1.36–7.05) when we
assumed that all treatment prolonged discontinuations during drug
shortage periods, as reported by the pharmacy, were due to drug
stock-outs, regardless of the explanation in the patient’s medical
record (Table 3).
When we restricted the analysis to only those patients whose
initial cART regimen included drugs that had been out of stock
(n=405), discontinuations caused by drug stock-outs were
independently associated with a higher risk of interruption in
care or death compared to no discontinuations or modifications
(adjusted HR, 5.23; 95% CI, 2.06–13.30), but stock-out-related
regimen modifications were not (adjusted HR, 1.48; 95% CI,
0.47–4.61; Table 4).
We evaluated the separate impacts of drug stock-outs on
retention in care and deaths. We found an association between
drug stock-outs and retention to care, but not between drug stock-
outs and death (data not shown). The lack of association between
drug stock-outs and death is likely due to a lack of statistical power.
Discussion
In this study conducted in Abidjan, Co ˆte d’Ivoire, we found that
at least 11% of the 1,554 patients who started cART between
February 1, 2006 and June 1, 2007 were affected by stock-outs of
at least one of their antiretroviral drugs. Because we could no
assess the reason for treatment discontinuation for a majority of
patients, the proportion of those affected by stock-outs may be
higher than 11%. Nevirapine and fixed-dose combination
zidovudine/lamivudine were out of stock most frequently. Generic
fixed-dose stavudine/lamivudine/nevirapine was always in stock.
Prolonged discontinuations related to drug stock-outs were
independently associated with a higher risk of interruption in
care or death compared to no discontinuations or modifications.
Table 4. Factors independently associated with interruption in care or death among 405 HIV-infected patients whose initial cART
regimen was affected by drug stock-outs, Abidjan, Co ˆte d’Ivoire.
Basecase Analysis Sensitivity analysis**
Interruption in care/death, n (%) HR 95% CI p HR 95% CI p
Yes No
cART discontinuation or
modification
None 14 (10.14) 124 (89.86) 1.00 0.01
* 1.00 ,0.01
*
Modification/stock-out 4 (9.30) 39 (90.70) 1. 48 0.47–4.61 0.50 1. 49 0.48–4.66 0.50
Modification/other reasons 2 (10.53) 17 (89.47) 2.62 0.59–11.75 0.21 2.64 0.59–11.84 0.20
Discontinuation /stock-out 8 (17.78) 37 (82.22) 5.23 2.06–13.30 ,0.01 5.54 2.17–14.15 ,0.01
Discontinuation/other reasons 32(20.25) 126 (79.75) 2.89 1.50–5.57 ,0.01 2.89 1.50–5.58 ,0.01
Gender
Female 38 (13.01) 254 (86.99) 1.00 0.01 1.00 0.01
Male 22 (19.82) 89 (80.18) 1.98 1.15–3.40 2.00 1.16–3.44
Study center
CePReF 18 (9.23) 177 (90.77) 1.00 0.10
* 1.00 0.10
*
CNTS 4 (25.00) 12(75.00) 1.97 0.62–6.32 0.25 1.99 0.62–6.40 0.25
Yopougon-Attie 38 (19.79) 154 (80.21) 1.97 1.05–3.71 0.04 2.01 1.06–3.80 0.03
First-line cART regimen
ZDV/3TC/EFV 29 (11.65) 220 (88.35) 1.00 ,0.01
* 1.00 0.01
*
d4T/3TC/EFV 14 (15.05) 79 (84.95) 1.86 0.95–3.65 0.07 1.87 0.95–3.69 0.07
ZDV/3TC/NVP 4 (23.53) 13 (76.47) 1.79 0.60–5.33 0.29 1.79 0.60–5.32 0.30
Other 13 (29.55) 31 (70.45) 3.22 1.63–6.36 ,0.01 3.24 1.64–6.40 ,0.01
Virological failure (6 months)
No 38 (12.06) 277 (87.94) 1.00 0.01 1.00 0.01
Yes 22 (25.00) 66 (75.00) 2.05 1.16–3.60 2.04 1.16–3.57
HR: hazard ratio, adjusted for all variables in the table;
CNTS: HIV clinic affiliated with the National Center for Blood Transfusion;
ZDV: zidovudine; 3TC: lamivudine; d4T: stavudine; EFV: efavirenz; NVP: nevirapine.
Other cART regimens: zidovudine-lamivudine-indinavir/ritonavir, lamivudine-stavudine-indinavir/ritonavir, or stavudine-abacavir-efavirenz.
Other reasons for modifications are: adverse events, tuberculosis, pregnancy and treatment failure. The reason for modification was unknown for 18 patients (6%).
Other reasons for discontinuations are: travel, adverse events, funeral, treatment with traditional remedies, or inability to pay for drugs. The reason for discontinuation
was unknown for 657patients (79%).
Virologic failure: plasma HIV RNA.300 copies/ml.
*Overall p value.
**The sensitivity analysis uses an expanded definition of drug stock-out, which includes any treatment discontinuation that lasted more than one month, was not
accompanied by an explanation in the medical record, occurred when the pharmacy reported a shortage of at least one of the drugs in the patient’s cART regimen.
doi:10.1371/journal.pone.0013414.t004
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significant impact on interruption in care or death.
Few studies have reported on the frequency and management of
antiretroviral drug stock-outs in sub-Saharan Africa. In Co ˆte
d’Ivoire [6,7] and Rwanda [5], studies focusing mainly on cART
adherence reported that drug stock-outs led to 10%–28% and
52% of cART discontinuations. The large difference between the
results of these studies may be related to the definition of drug
stock-out used. Drug stock-outs may also change over time and by
setting.
Drug stock-outs in this study can in part be explained by
structural problems that affected all Aconda centres. The drug
stock-outs that occurred at the time of the study were related to
structural problems affecting all 20 Aconda centres. From May
2004 to January 2006, the HIV care centres included in the study
received their drugs directly from the United States, through
HEART PEPFAR. Starting in January 2006, the National HIV
Care Program of Co ˆte d’Ivoire established the Central Public
Health Pharmacy (CPHP) as the main drug supplier for HIV care
centres in Abidjan. The drug needs of all Aconda centres were
thus sent to the CPHP, leading to antiretroviral drug supply
interruptions between 2006 and 2007, due to the large volume of
orders. Furthermore, PEPFAR did not consistently provide a
sufficient amount of drugs to the CPHP, due to financial
limitations. The current global economic crisis may lead
government and international organizations to withdraw some of
their funding from treatment programs in developing countries. As
a result, drug stock outs and treatment interruptions may increase.
In this study, generic fixed-dose stavudine/lamivudine/nevir-
apine, which is often used for first-line cART in sub-Saharan
Africa, was always in stock. We acknowledge that our results
cannot be necessarily extrapolated to other settings and that stock-
outs are likely to continue even with the establishment of a
standard fixed-dose first line regimen. Nevertheless, in low-income
countries, where access to cART is increasing rapidly, stock
management may be facilitated and stock-outs may decline if
national guidelines recommend one combination for all patients
initiating first-line therapy. Harries et al. recently described a
model of rational antiretroviral drug forecasting in Malawi [24].
This model is similar to the model adopted by the country’s
Tuberculosis Control Program, and suggests using fixed-dose
stavudine/lamivudine/nevirapine as a standard first-line cART
regimen. The authors did not report any antiretroviral drug stock-
outs in Malawi during the study period, from July to December
2006. The WHO recently updated guidelines on antiretroviral
therapy for HIV infection in adults and adolescents [25]
recommend that countries in sub-Saharan Africa should develop
a plan to move towards zidovudine or tenofovir-based first-line
regimens rather than stavudine-based regimen while the goal of
this is to avoid drug toxicity. The results of the current study
suggest that first-line regimens should be standardized in this
transition to decrease the probability of stock-outs.
During the study period, 12% of patients died and 23%
interrupted care. Most of these events occurred in the first six
months of cART. These estimates are consistent with those
reported in other pilot cART programs [12,14,17,18,20,26]. We
evaluated the impact of stock-outs on interruption in care or death
in the 975 patients who were on cART for at least six months. The
risk of interruption in care or death was three times higher for
patients who discontinued cART because of drug stock-outs, but
stock-out-related cART modifications did not affect patient
outcomes. Interventions to decrease the frequency of drug stock-
outs, such as standard first-line cART regimens, should be
implemented. Written protocols should recommend cART specific
regimens in situations where first- and second-line cART regimens
are out of stock. HIV centers should also keep alternative
antiretroviral drugs in stock so that clinicians can modify regimens,
rather than interrupting them, during stock-outs. In our study,
physicians managed most stock-outs by modifying rather than
interrupting therapy. Over the course of the study, when stock-
outs occurred, the proportion of patients who discontinued
treatment decreased and the proportion of patients who modified
their regimens increased. This trend may illustrate physicians’
tendency to capitalise on their experience in order to better
manage drug stock-outs.
This study suggests that men are at higher risk of interruption in
care and death than women, as previously reported
[12,17,27,28,29]. Moreover, the rate of virologic response six
months after treatment initiation, a well known predictor of
efficacy and adherence [9,30,31], was independently associated
with interruption in care or death. In 2008, De Beaudrap et al.
reported in a Senegalese cohort, that body mass index and CD4
count were predictive of death during the first 6 months of follow-
up after cART initiation, but after 6 months, the viral load was a
stronger predictor of mortality and the effect of CD4 count was
less pronounced [32].
Finally, as shown in previous studies, treatment modifications
that were not related to drug stock-outs were independently
associated with death [10,12,33]. Treatment discontinuations not
due to stock-outs, but rather to non-adherence or other reasons,
were also associated with interruption in care or death, as
previously described [12,16,17,34]. Cesar et al. recently reported
in that almost 28% of 5,026 patients who initiated cART in a
Caribbean and a Latin American cohort modified their first-line
regimen one year after initiation, mainly because of adverse events
[35]. Other studies conducted in resource-limited settings, have
reported that 20–28% of patients modify their first-line regimen
[36,37]. In our study, 280 (28%) of 1,554 patients modified their
cART regimens at least once during the follow-up (median 13
months). This result is consistent with data reported in the
literature.
Of note, we also found an increased risk of interruption in care
or death when patients initiated cART with abacavir or indinavir.
Although data are limited, indinavir-containing regimens have
been shown to be associated with lower rates of adherence than
stavudine/lamivudine/nevirapine [38].
This analysis has several limitations. First, we collected stock-out
data was retrospectively. We were not able, to assess the reason for
treatment discontinuations for a majority of patients. We may,
therefore, have underestimated the proportion of patients for
whom treatment discontinuations were due to drug stock-outs.
This limitation may have affected the association we found
between stock-out-related discontinuations and interruption of
care or death. We attempted to minimise bias by choosing the
group of patients who did not interrupt cART as the reference.
Furthermore, the association between stock-out-related cART
discontinuations and interruptions of care or death remained
robust when we modified the definition of drug stock-out (Table 3).
Second, inclusion in the analysis of all patients on cART rather
than just those taking antiretroviral drugs that were not always in
stock may have attenuated the estimated association between drug
stock-outs and interruption in care or death. When we only
included patients on cART regimens affected by drug stock-outs,
the risk of interruption in care or death was higher for patients
who interrupted cART because of drug stock-outs, but not for
patients who interrupted cART for other reasons. In this sensitivity
analysis, stock-out-related regimen modifications were not associ-
ated with interruption in care or death.
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PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13414In conclusion, this study suggests that drug stock-outs affect a
substantial proportion of patients on cART in Abidjan, even
though generic the fixed-dose recommended as first-line therapy in
Co ˆte d’Ivoire, stavudine/lamivudine/nevirapine, was always in
stock. Stock-out-related cART discontinuations had a significant
impact on retention in care and death, but cART regimen
modifications did not. With the movement towards newer, less
toxic first-line regimens in sub-Saharan Africa, it is crucial that
those regimens be standardised to avoid drug stock-outs and their
consequences.
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